EDX Medical Group’s Post

𝐏𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐀𝐕𝐀6000 𝐢𝐧 𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐅𝐀𝐏-𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫𝐬 Avacta presented updated data from the ongoing Phase 1a trial of AVA6000 at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. This innovative treatment, targeting Fibroblast Activation Protein (FAP), shows potential in patients with FAP-positive solid tumors. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: • AVA6000 demonstrated a favorable safety profile with no significant cardiac toxicity, a common concern with conventional doxorubicin. • Encouraging efficacy was observed, with 3 partial responses and 4 minor responses in patients with FAPhigh cancers. • A notable durable response was recorded in a 79-year-old male patient with salivary gland cancer, showing a 46.2% reduction in tumor size over 18 weeks. • AVA6000 treatment led to significantly lower incidences of severe neutropenia and cardiac events compared to conventional doxorubicin. About AVA6000: • AVA6000 is the first peptide drug conjugate in Avacta's pipeline, consisting of doxorubicin conjugated to a peptide that is specifically activated in the tumor microenvironment. • AVA6000 utilizes Avacta's proprietary pre|CISION™ platform technology. • The pre|CISION technology aims to release the drug specifically in tumor tissues, minimizing systemic side effects and improving tolerability. These findings reinforce the potential of AVA6000 to transform cancer treatment by enhancing efficacy while reducing adverse effects. Christina Coughlin, CEO of Avacta, highlighted the promising implications for the platform in expanding access to effective therapies for patients. #CancerResearch #Oncology #ClinicalTrials #FAP #ESMO2024

Exciting collaboration alert! Owkin and AstraZeneca are teaming up on an AI-powered tool to pre-screen for harmful mutations in breast cancer genes using digital pathology slides. This innovative solution aims to enhance accessibility and streamline testing, ensuring more patients can benefit from personalized care. BRCA testing plays a crucial role in identifying cancer risk and guiding treatment decisions. However, accessibility to testing can be inconsistent, leading to missed opportunities for tailored care. The gBRCA pre-screening tool is set to significantly increase the number of patients identified with harmful mutations by 2030, accelerating the testing process and reducing time to results. By offering faster and more accessible testing, this solution will advance precision medicine by identifying high-risk individuals and enabling tailored treatment plans. Moreover, it aims to reduce disparities in care, ensuring more patients can access personalized treatments based on their genetic profile. This partnership exemplifies a shared commitment to revolutionizing BRCA testing, improving patient care, and ultimately saving lives. Learn more about this groundbreaking collaboration here: https://lnkd.in/d9PNRPBv Michael Holsey, PhD Alban de La Sablière #PrecisionMedicine #BreastCancerResearch #HealthcareInnovation

🔬 #ASCO2024: Key Insights! 🔬 I just returned from ASCO, and here's what grabbed my attention and why I am even more excited about our ability to advance patient care in Oncology. 1️⃣ #Immunotherapy Triumphs: Checkpoint inhibitors continue to deliver impressive results. For instance, data from a Phase III trial showed a 30% reduction in mortality rates among advanced melanoma patients receiving combination immunotherapy compared to standard treatment (Source -https://lnkd.in/d2a6swNU). 2️⃣ #PrecisionMedicine Revolution: Take the success of the PARP inhibitor olaparib in metastatic breast cancer patients with BRCA mutations as an example. The study reported a 42% reduction in the risk of disease progression or death compared to chemotherapy (Source - https://lnkd.in/dp7fSKuk). 3️⃣ #ADCs: The Rising Stars: Antibody-drug conjugates (ADCs) are making waves, and for good reason. An ADC targeting HER2-positive breast cancer demonstrated a 50% response rate in patients who had previously failed multiple lines of therapy (Source - https://lnkd.in/dKXQTMSD). Implications for Biopharma? 1) Double down on innovation. With #immunotherapy, #precisionmedicine, and #ADCs leading the charge, biopharma companies must prioritize R&D efforts in these areas. 2) Increase ecosystem collaboration with #digitalpathology and #precesiondiagnostics leaders, i.e., Leica Biosystems and Danaher Diagnostics, to enable at-scale access to these novel therapies at launch. 3) Collaborate and invest in building a market for faster #digitalpathology adoption and #AI-powered diagnostics in a way that supports scale (i.e., workflow, reimbursement considerations) We look forward to collaborating with our #biopharma and #AI partners to drive progress together! And advance this new era of #OncologyPrecesionDiagnostics. 💡 #ASCO2024 #PrecisionMedicine #DigitalPathology #ADCs #AI #OncologyInnovation #computationalpathology #PrcesionDiagnostics J. Gustavo Perez Rob Monroe, MD, PhD Rachel Skelton Traci Degeer

Our team will be at #ASCO24 May 31 - June 4 where Dr. Elena Garralda Cabanas will be delivering a poster presentation of the phase one study data for EP0031/A400. EP0031 is developed in partnership with Kelun-Biotech and was cleared to start phase-2 clinical development by the FDA earlier this month. Don't miss Dr. Garralda at 1.30pm on June 3rd. EP0031 is a potential treatment of RET-altered tumours. Clinical data in studies to date has shown promising efficacy in patients with NSCLC, thyroid and other solid tumours. Durable responses have been seen in patients who were naive to, or who had been pre-treated with, 1st generation SRIs including in patients with brain metastases. Activating RET mutations and rearrangements have been identified as actionable drivers of oncogenesis in numerous tumour types and are most prevalent in non-small cell lung and thyroid cancer. It is estimated that RET mutations and rearrangements may be responsible for ~2% of all solid tumours. After the successful development of first generation SRIs and an increasing understanding of escape mechanisms to these agents, there is an unmet need to develop new treatments that can address acquired resistance, including the development of next-generation SRIs. Seek out our team to find out how we are driving innovation forward in the development of oncology medicines. We'll see you at #ASCO24

🚀 Exciting Developments in Lung Cancer Screening 🚀 At Lampgen Clinical Research, we're thrilled to see the innovative strides being made by Delfi Diagnostics in the realm of lung cancer screening. Their recent announcement about the key data and study design for their liquid biopsy test represents a significant leap forward in the fight against this devastating disease. Delfi Diagnostics is focusing on a critical need—screening for lung cancer with a blood test that can stratify patients into higher-risk and lower-risk groups. This approach has the potential to increase the number of patients who receive essential low-dose CT scans, thus enhancing early detection and improving outcomes. The investment by Merck Global Health Innovation Fund and the recruitment of industry leaders like Susan Tousi and Peter Bach underscore the high potential and credibility of Delfi's work. With sensitivity at 80% and specificity at 58%, their test aims to ensure that more people at risk get the necessary screenings. As a staffing firm dedicated to providing expert oncology CRAs to sponsors and CROs, Lampgen Clinical Research is committed to supporting groundbreaking initiatives like this. Ensuring cancer clinical trials are monitored with ICH/GCP and industry-standard expertise is our mission, and we take pride in being the staffing firm of choice for companies conducting these pivotal trials. #OncologyResearch #ClinicalTrials #CancerScreening #LungCancer #LiquidBiopsy #CancerDetection #Biotechnology #HealthInnovation #ClinicalResearch #LampgenClinicalResearch #ICHGCP #OncologyStaffing #CancerCare #EarlyDetection #MedicalAdvancement 🔗 https://lnkd.in/gPVJCXgy

🚨𝐄𝐱𝐚𝐜𝐭 𝐒𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐢𝐬 𝐠𝐞𝐚𝐫𝐢𝐧𝐠 𝐮𝐩 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐥𝐚𝐮𝐧𝐜𝐡 𝐨𝐟 𝐧𝐞𝐰 𝐚𝐬𝐬𝐚𝐲𝐬, 𝐛𝐮𝐨𝐲𝐞𝐝 𝐛𝐲 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐞𝐝 𝐠𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐢𝐭𝐬 𝐞𝐱𝐢𝐬𝐭𝐢𝐧𝐠 𝐭𝐞𝐬𝐭𝐬🚨... 🧪Exact Sciences is preparing for the introduction of a fresh set of assays in the coming years, which includes an updated version of its renowned stool-based colorectal #cancer screening test, #cologuard , alongside a complementary blood-based assay and a detection test for minimal residual disease. 🥼#CEO Kevin Conroy discussed these upcoming assays and 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐚 17 𝐩𝐞𝐫𝐜𝐞𝐧𝐭 𝐲𝐞𝐚𝐫-𝐨𝐯𝐞𝐫-𝐲𝐞𝐚𝐫 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐠𝐫𝐨𝐰𝐭𝐡, which, according to Conroy, "𝒔𝒆𝒕𝒔 𝒕𝒉𝒆 𝒔𝒕𝒂𝒈𝒆 𝒇𝒐𝒓 𝒂 𝒔𝒊𝒈𝒏𝒊𝒇𝒊𝒄𝒂𝒏𝒕 𝒚𝒆𝒂𝒓 𝒂𝒉𝒆𝒂𝒅." ✔️Conroy also mentioned that 𝐄𝐱𝐚𝐜𝐭 𝐬𝐮𝐛𝐦𝐢𝐭𝐭𝐞𝐝 𝐢𝐭𝐬 𝐩𝐫𝐞𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐢𝐭𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐨𝐥𝐨𝐠𝐮𝐚𝐫𝐝 𝐭𝐨 𝐭𝐡𝐞 FDA 𝐢𝐧 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫. 📈𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐲 𝐚𝐧𝐭𝐢𝐜𝐢𝐩𝐚𝐭𝐞𝐬 𝐦𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐞𝐬𝐭 𝐚𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐥𝐞 𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐛𝐲 2025. This submission is backed by data from the company's BLUE-C trial, revealed last year, showcasing the following: - 94 percent sensitivity for detecting cancers - 93 percent sensitivity for identifying curable-stage cancers - 43 percent sensitivity for advanced precancerous lesions - 91 percent specificity, an improvement from the 87 percent specificity observed in the FDA registrational trial for the initial version of Cologuard. 🧬Furthermore, the company plans to disclose data from various studies on its minimal residual disease test, #oncodetect, within the next 12 months. Conroy mentioned that 𝐭𝐡𝐢𝐬 𝐝𝐚𝐭𝐚 𝐰𝐢𝐥𝐥 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐫𝐞𝐢𝐦𝐛𝐮𝐫𝐬𝐞𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐚𝐬𝐬𝐚𝐲 𝐢𝐧 𝐜𝐨𝐥𝐨𝐧 𝐜𝐚𝐧𝐜𝐞𝐫. While Exact doesn't intend to pursue reimbursement in other cancer types this year, it's actively accumulating data for OncoDetect in other tumours such as #breastcancer. 𝐈𝐧 𝐥𝐢𝐠𝐡𝐭 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧, 𝐡𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐟𝐨𝐫𝐞𝐬𝐞𝐞 𝐭𝐡𝐞 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐧𝐞𝐰 𝐚𝐬𝐬𝐚𝐲𝐬 𝐢𝐦𝐩𝐚𝐜𝐭𝐢𝐧𝐠 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 𝐚𝐜𝐫𝐨𝐬𝐬 𝐯𝐚𝐫𝐢𝐨𝐮𝐬 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐬𝐞𝐭𝐭𝐢𝐧𝐠𝐬? #IVD 🔗Source: https://lnkd.in/etP4g5cy.

We are excited to announce that the first patient has been imaged in a Phase 1 study evaluating our 61Cu-based radiotracer in patients with PSMA-positive prostate cancer. This is the first candidate from our broad theranostic pipeline to enter the clinic. 61Cu-NuriPro is the diagnostic component of our NuriPro program, binding specifically to Prostate Specific Membrane Antigen (PSMA). Upon successful completion of the trial we will advance our NuriPro program into a Phase 1/2 theranostic clinical trial, evaluating both the 61Cu-based imaging alongside the 67Cu-based therapeutic candidate. The non-randomized study is initiated by Gary Ulaner and is being conducted at Hoag Memorial Hospital Presbyterian in Newport Beach, California. It will evaluate the safety and effectiveness of our candidate compared to an 18F-based, FDA-approved PSMA-targeting radiotracer. 61Cu-NuriPro has the potential to overcome both detection and production challenges of currently available agents. It enables delayed imaging, allowing for the detection of even the smallest metastases. With a 3.3-hour half-life, compared to the 1-to-2-hour half-life of most molecular imaging agents, it allows for a far greater distribution range following production. In addition, it can be easily manufactured at room temperature, enabling on-demand preparation and a simplified and easy-to-apply workflow with reduced need for laboratory equipment. #CancerCare #CancerDiagnostics #Prostatecancer #MedicalImaging #PrecisionOncology #Radiopharmaceuticals #Radiotheranostics #Theranostics

✨𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗧-𝗖𝗲𝗹𝗹 𝗘𝗻𝗴𝗮𝗴𝗲𝗿 (𝗧𝗖𝗘) 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝘁 𝗩𝗶𝘃𝗶𝗮: 𝗔 𝗟𝗲𝗮𝗱𝗶𝗻𝗴 𝗖𝗥𝗢 𝗶𝗻 𝗘𝘅 𝗩𝗶𝘃𝗼 𝗧𝗖𝗘 𝗔𝗰𝘁𝗶𝘃𝗶𝘁𝘆✨ At Vivia, we're proud to be a recognized center of excellence for evaluating T-Cell Engagers (TCEs) ex vivo. Our extensive experience spans various indications, including AML, multiple myeloma, CLL, NHL, colorectal and lung cancer, melanoma, and more. We've successfully assessed over 30 different TCEs across a wide range of cancer types, contributing to numerous industry-leading studies and publications. Our TCE assays are fully compliant with FDA requirements, ensuring rigorous and reliable results. We offer: • 𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗮𝗺𝗽𝗹𝗲𝘀: Both fresh and frozen samples, with comprehensive molecular characterization and complete clinical data. • 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗔𝘀𝘀𝗮𝘆𝘀: Utilizing advanced flow cytometry techniques, including target expression, T cell activation, dual targeting strategies, cross-linking assays, and more. • 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗧𝗲𝘀𝘁𝗶𝗻𝗴: Covering selective killing, CDC/ADCC assays, cytokine release assays, and the detection of immune-mediated damage in non-target cells. Our work continues to push the boundaries of TCE research, helping to advance immunotherapy and improve patient outcomes. 🔬 Schedule a meeting with our team: https://lnkd.in/g-J9xBPm 🔬 For custom assays in Hematologic Malignancies, click here: https://lnkd.in/gq4N5YRs #TCE #Immunotherapy #ClinicalResearch #Oncology #ExVivoAssays #Vivia 

We spent the early part of this week energized by the wealth of insights and breakthroughs presented in oncology at #ESMO2024. Highlights from Monday's announcements and presentations include: ✅ In combination with chemotherapy, Jazz Pharmaceuticals shared phase 2 data on Zanidatamab that show the HER2-targeted bispecific antibody has 59% of people with metastatic gastroesophageal cancer (mGEA) alive for at least 30 months. The next step? Phase 3 trial in combination with chemotherapy and BeiGene's Tevimbra as a first-line treatment for HER-2 positive mGEA. Results are expected in 2Q 2025.   ✅ In an effort to diversify methods for catching early cases of colorectal cancer, Exact Sciences shared clinical data showing its blood-based test can help spot growing tumors and some precancerous lesions. Data comes from Exact Sciences' BLUE-C study—an expansive colorectal cancer trial of more than 26K patients. On the forecasting front, here are some key takeaways from #ESMO2024 that will help shape our work in forecasting for life sciences: ✅ Precision medicine is becoming more targeted and personalized, requiring more sophisticated forecasting models to anticipate patient outcomes and treatment demand. ✅ The rapid advancements in immunotherapies and combination treatments are reshaping the landscape, emphasizing the need for adaptable forecasting strategies. ✅ Data-driven insights and real-world evidence are playing an increasingly pivotal role in guiding treatment decisions, making accurate and reliable forecasts even more crucial. As we continue to refine our approach, we’re excited to apply these takeaways to better serve our clients and contribute to the ongoing innovation in healthcare. #ESMO2024 #Oncology #Forecasting #LifeSciences #DataDriven #PrecisionMedicine #HealthcareInnovation #Viscadia

🎙 Recently I spoke with Navid as we delved into the fascinating world of using AI to power early detection and provide better treatments in oncology and cardiology. Here are three key takeaways from our insightful conversation with Navid: ⭐ Early Detection is Key: Navid shared how his platform is revolutionizing breast cancer detection using AI technology. With their FDA-cleared products, they can detect breast cancer and even early signs of heart disease from mammograms. This early detection can potentially save lives by enabling timely interventions and treatments. ⭐ Personalized Precision Medicine: Through his platform, Navid and his team are pioneering personalized precision medicine in oncology. By analyzing the molecular makeup of a patient's cancer through next-gen sequencing, they provides oncologists with tailored treatment recommendations. This approach not only improves patient outcomes but also helps pharma companies bring cancer drugs to market faster. ⭐ The Power of AI and Collaboration: Navid emphasized the importance of partnerships and collaborations in expanding the reach and impact of their AI-driven solutions. By working with larger pharmaceutical companies and healthcare providers, they aim to make a significant difference in improving women's health and advancing cancer care globally. If you want to learn more about the groundbreaking work being done by Navid and his teams you can listen to the full episode at the link below. https://lnkd.in/d_Nxj7TW 💥 #AIinHealthcare #AIinoncology #EarlyDetection #HealthTechInnovation